Key Points
- David Malcom Rodman sold 2,171 shares on March 9 at an average price of $26.84 (≈$58,270), reducing his position by 2.56%
- Rodman has repeatedly sold large blocks of stock in recent months—most notably 70,037 shares on Jan. 2 at $35.87—indicating substantial insider divestment over the period.
- Mineralys (MLYS) is trading near $28.43 with a 50‑day/200‑day SMA of $30.99/$35.40, a market cap of about $2.25B, and a consensus analyst rating of "Moderate Buy" with an average price target of $47.43.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 2,171 shares of the business's stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $26.84, for a total transaction of $58,269.64. Following the completion of the transaction, the insider directly owned 82,489 shares of the company's stock, valued at $2,214,004.76. This trade represents a 2.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
David Malcom Rodman also recently made the following trade(s):
- On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total value of $11,505.03.
- On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.99, for a total value of $184,057.51.
- On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total value of $385,669.20.
- On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total value of $65,585.91.
- On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total value of $13,353.60.
- On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total value of $370,677.87.
- On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total value of $252,469.75.
- On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.32, for a total transaction of $205,167.36.
- On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $33.27, for a total transaction of $72,195.90.
- On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.87, for a total transaction of $2,512,227.19.
Mineralys Therapeutics Stock Performance
NASDAQ:MLYS opened at $28.43 on Wednesday. The company's 50-day simple moving average is $30.99 and its 200-day simple moving average is $35.40. Mineralys Therapeutics, Inc. has a fifty-two week low of $10.44 and a fifty-two week high of $47.65. The stock has a market capitalization of $2.25 billion, a P/E ratio of -9.64 and a beta of 0.57.
Institutional Investors Weigh In On Mineralys Therapeutics
A number of large investors have recently bought and sold shares of MLYS. Navalign LLC acquired a new position in Mineralys Therapeutics in the 4th quarter worth approximately $33,000. Smartleaf Asset Management LLC lifted its stake in Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company's stock valued at $40,000 after acquiring an additional 676 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in shares of Mineralys Therapeutics by 42.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company's stock valued at $54,000 after acquiring an additional 1,197 shares during the last quarter. Royal Bank of Canada increased its stake in shares of Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock worth $56,000 after acquiring an additional 1,107 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Mineralys Therapeutics by 1,845.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company's stock worth $76,000 after purchasing an additional 1,993 shares during the last quarter. Hedge funds and other institutional investors own 84.46% of the company's stock.
Wall Street Analysts Forecast Growth
MLYS has been the subject of several recent analyst reports. Stifel Nicolaus raised their target price on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research note on Friday, December 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. HC Wainwright set a $56.00 price objective on Mineralys Therapeutics and gave the stock a "buy" rating in a research report on Tuesday. Wells Fargo & Company boosted their target price on Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 11th. Finally, Wall Street Zen lowered Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $47.43.
View Our Latest Analysis on Mineralys Therapeutics
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
